Acquired Company
Channel Therapeutics completed its merger with LNHC, Inc., resulting in Pelthos Therapeutics Inc., and the combined company began trading on the NYSE American under the ticker PTHS on July 2, 2025.
Pelthos Therapeutics Inc. is an innovative biotechnology firm based in Durham, North Carolina, that focuses on the development and commercialization of transformative therapeutic solutions targeting significant unmet medical needs. By leveraging advanced biopharmaceutical technologies and cutting-edge research, the company aims to address complex health challenges and deliver improved outcomes for patients. Pelthos is well-positioned within the rapidly evolving therapeutic development landscape, strategically targeting expansion opportunities that align with its mission to enhance shareholder value through pioneering treatments. Show more
Location: 4020 STIRRUP CREEK DRIVE, DURHAM, NC, UNITED STATES, 27703, Durham, NC, 27703, USA | Website: https://pelthos.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
75.46M
52 Wk Range
$9.00 - $37.50
Previous Close
$23.32
Open
$22.25
Volume
6,392
Day Range
$22.25 - $23.30
Enterprise Value
64.7M
Cash
14.25M
Avg Qtr Burn
-15.26M
Insider Ownership
54.35%
Institutional Own.
24.99%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Xeglyze/Abametapir (Metalloproteinase Inhibitor) Details Head Lice Infestation | Approved Update |